{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:10:42Z","timestamp":1789143042844,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004505","name":"Universit\u00e0 degli Studi di Catania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004505","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Aztreonam\/avibactam represents a valuable therapeutic option for infections caused by metallo-\u03b2-lactamase-producing\n                      <jats:italic>Enterobacterales<\/jats:italic>\n                      , but data on its use during continuous renal replacement therapy (CRRT) are scarce and largely limited to a single pharmacokinetic report. Here, we describe the clinical course of a 76-year-old woman with end-stage renal disease who received aztreonam\/avibactam while undergoing continuous venovenous haemodiafiltration (CVVHDF) during a critical illness secondary to a presumed invasive infection by NDM-producing\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Ceftazidime\/avibactam plus aztreonam was started empirically for fever, pyuria and a urinary NDM-producing\n                      <jats:italic>K. pneumoniae<\/jats:italic>\n                      isolate, then switched to co-formulated aztreonam\/avibactam after surgery and ICU transfer (intermittent-haemodialysis phase: loading 1\u00a0g\/0.333\u00a0g, then 0.675\/0.225\u00a0g every 12\u00a0h as a 3-h infusion). When CVVHDF was started for worsening sepsis, the regimen was changed to a 2\u00a0g\/0.667\u00a0g loading dose followed by 1\u00a0g\/0.333\u00a0g every 8\u00a0h given as an uninterrupted continuous infusion, replicating the only previously reported CVVHDF regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The course was confounded by vancomycin-resistant\n                      <jats:italic>Enterococcus faecium<\/jats:italic>\n                      bacteraemia, bowel ischaemia with perforation, stercoral peritonitis and polymicrobial intra-abdominal infection. No microbiologically documented recurrence of the NDM-producing organism occurred after treatment, although rectal colonization persisted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The case demonstrates the practical feasibility of continuous-infusion aztreonam\/avibactam during CVVHDF. Efficacy and PK\/PD target attainment cannot be confirmed, as susceptibility testing for the index strain and therapeutic drug monitoring were unavailable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02971-z","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:29:35Z","timestamp":1789140575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aztreonam\/avibactam during continuous venovenous haemodiafiltration in a critically ill patient with NDM-producing Klebsiella pneumoniae: a case report and review of the literature"],"prefix":"10.1007","author":[{"given":"Federica","family":"Cosentino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Marino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Moscatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiovanna","family":"Coco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Prestifilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Franz\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cacopardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Nunnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2971_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18:318\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(17)30753-3.","journal-title":"Lancet Infect Dis"},{"key":"2971_CR2","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024;ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"2971_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/phar.4629","volume":"44","author":"M Al Musawa","year":"2024","unstructured":"Al Musawa M, Bleick CR, Herbin SR, Caniff KE, Van Helden SR, Rybak MJ. Aztreonam\u2013Avibactam: The dynamic duo against multidrug-resistant gram\u2010negative pathogens. Pharmacother J Hum Pharmacol Drug Ther. 2024;44:927\u201338. https:\/\/doi.org\/10.1002\/phar.4629.","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2971_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","volume":"31","author":"G Sangiorgio","year":"2025","unstructured":"Sangiorgio G, Calvo M, Stefani S. Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: a narrative review. Clin Microbiol Infect. 2025;31:971\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2024.11.006.","journal-title":"Clin Microbiol Infect"},{"key":"2971_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/antibiotics10081012","volume":"10","author":"C Mauri","year":"2021","unstructured":"Mauri C, Maraolo AE, Di Bella S, Luzzaro F, Principe L. The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases. Antibiotics. 2021;10:1012. https:\/\/doi.org\/10.3390\/antibiotics10081012.","journal-title":"Antibiotics"},{"key":"2971_CR6","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","volume":"75","author":"OA Cornely","year":"2020","unstructured":"Cornely OA, Cisneros JM, Torre-Cisneros J, Rodr\u00edguez-Hern\u00e1ndez MJ, Tall\u00f3n-Aguilar L, Calbo E, Horcajada JP, Queckenberg C, Zettelmeyer U, Arenz D, et al. Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother. 2020;75:618\u201327. https:\/\/doi.org\/10.1093\/jac\/dkz497.","journal-title":"J Antimicrob Chemother"},{"key":"2971_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00228-023-03609-x","volume":"80","author":"S Das","year":"2024","unstructured":"Das S, Riccobene T, Carrothers TJ, Wright JG, MacPherson M, Cristinacce A, McFadyen L, Xie R, Luckey A, Raber S. Dose Selection for Aztreonam-avibactam, including adjustments for renal impairment, for phase IIa and phase III evaluation. Eur J Clin Pharmacol. 2024;80:529\u201343. https:\/\/doi.org\/10.1007\/s00228-023-03609-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"2971_CR8","volume-title":"Emblaveo (Aztreonam\/Avibactam): Summary of Product Characteristics","author":"European Medicines Agency","year":"2024","unstructured":"European Medicines Agency. Emblaveo (Aztreonam\/Avibactam): summary of product characteristics. Amsterdam: European Medicines Agency; 2024. Last updated: 23\/02\/2026."},{"key":"2971_CR9","doi-asserted-by":"publisher","unstructured":"Adembri C, Novelli A, Nobili S. Some suggestions from PK\/PD principles to contain resistance in the clinical setting\u2014focus on ICU patients and gram-negative strains. Antibiotics. 2020;9. https:\/\/doi.org\/10.3390\/antibiotics9100676.","DOI":"10.3390\/antibiotics9100676"},{"key":"2971_CR10","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1093\/jac\/dkv132","volume":"70","author":"R Singh","year":"2015","unstructured":"Singh R, Kim A, Tanudra MA, Harris JJ, McLaughlin RE, Patey S, O\u2019Donnell JP, Bradford PA, Eakin AE. Pharmacokinetics\/pharmacodynamics of a \u03b2-lactam and \u03b2-lactamase inhibitor combination: a novel approach for aztreonam\/avibactam. J Antimicrob Chemother. 2015;70:2618\u201326. https:\/\/doi.org\/10.1093\/jac\/dkv132.","journal-title":"J Antimicrob Chemother"},{"key":"2971_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13054-024-04911-5","volume":"28","author":"M Gatti","year":"2024","unstructured":"Gatti M, Cojutti PG, Pea F. Impact of attaining aggressive vs. conservative PK\/PD target on the clinical efficacy of beta-lactams for the treatment of gram-negative infections in the critically Ill patients: a systematic review and meta-analysis. Crit Care. 2024;28:123. https:\/\/doi.org\/10.1186\/s13054-024-04911-5.","journal-title":"Crit Care"},{"key":"2971_CR12","doi-asserted-by":"publisher","first-page":"e01950","DOI":"10.1128\/aac.01950-24","volume":"69","author":"R Xie","year":"2025","unstructured":"Xie R, Rogers H, Chow JW, Soto E, Raber SR. Population pharmacokinetic\/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients. Antimicrob Agents Chemother. 2025;69:e01950\u201324. https:\/\/doi.org\/10.1128\/aac.01950-24.","journal-title":"Antimicrob Agents Chemother"},{"key":"2971_CR13","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1093\/jac\/dkaf330","volume":"80","author":"D Fres\u00e1n","year":"2025","unstructured":"Fres\u00e1n D, Gracia-Arnillas MP, Iriarte Zugasti A, Raich Gual C, Comaju\u00e1n Mendoza C, Acer M, Mu\u00f1oz-Bermudez R, Montero MM, Sorl\u00ed L, Luque S. Pharmacokinetics of aztreonam\/avibactam in a critically Ill patient with a class B metallo-\u03b2-lactamase producing enterobacteriaceae and receiving continuous renal replacement therapy. J Antimicrob Chemother. 2025;80:3469\u201371. https:\/\/doi.org\/10.1093\/jac\/dkaf330.","journal-title":"J Antimicrob Chemother"},{"key":"2971_CR14","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40121-025-01294-0","volume":"15","author":"P Laffont-Lozes","year":"2026","unstructured":"Laffont-Lozes P, Villa F, Mory C, Sotto A, Loubet P, Pantel A, Larcher R. Continuous infusion of aztreonam\u2013avibactam after high loading dose for an infection caused by an OXA-48- and NDM-1-Co-producing ST147 Klebsiella Pneumoniae. Infect Dis Ther. 2026;15:639\u201349. https:\/\/doi.org\/10.1007\/s40121-025-01294-0.","journal-title":"Infect Dis Ther"},{"key":"2971_CR15","doi-asserted-by":"publisher","first-page":"1224922","DOI":"10.3389\/fmed.2023.1224922","volume":"10","author":"Y Merad","year":"2023","unstructured":"Merad Y, Conrad A, Brosset S, Schmidt A, Hanriat C, Lustig S, Laurent F, Kolenda C, Roussel-Gaillard T, Batailler C, et al. Case Report: Continuous Infusions of Ceftazidime-Avibactam and Aztreonam in Combination through Elastomeric Infusors for 12 Weeks for the Treatment of Bone and Joint Infections Due to Metallo-\u03b2-Lactamase Producing Enterobacterales. Front Med. 2023;10:1224922. https:\/\/doi.org\/10.3389\/fmed.2023.1224922.","journal-title":"Front Med"},{"key":"2971_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar J-WC, Bassetti M, Bracht H, Dimopoulos G, Marriott D, Neely MN, Paiva J-A, Pea F, Sjovall F, et al. Antimicrobial therapeutic drug monitoring in critically Ill adult patients: a position paper#. Intensive Care Med. 2020;46:1127\u201353. https:\/\/doi.org\/10.1007\/s00134-020-06050-1.","journal-title":"Intensive Care Med"},{"key":"2971_CR17","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3390\/jpm14121135","volume":"14","author":"O H\u00f6lsken","year":"2024","unstructured":"H\u00f6lsken O, Sponheuer K, Weber F, Martens-Lobenhoffer J, Bode-B\u00f6ger SM, Kloft C, Treskatsch S, Angermair S. First Clinical Application of Aztreonam\u2013Avibactam in Treating Carbapenem-Resistant Enterobacterales: Insights from Therapeutic Drug Monitoring and Pharmacokinetic Simulations. J Pers Med. 2024;14:1135. https:\/\/doi.org\/10.3390\/jpm14121135.","journal-title":"J Pers Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02971-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02971-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02971-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:29:36Z","timestamp":1789140576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02971-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":17,"alternative-id":["2971"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02971-z","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"26 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The report was prepared in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee Catania 2 (Approval Code: no. 101\/CECT2).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of anonymized clinical details was obtained from the patient.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}